CB Therapeutics’ lab-grown cannabinoids could unlock new medicines and make others affordable


Marijuana may still be on shaky legal ground, but the therapeutic benefits of the psychoactive molecules — cannabinoids — inside the plant are solidly established. Unfortunately, cultivation of that plant is resource-intensive and yields only tiny amounts of some useful medicines. CB Therapeutics, a new biotech company launching today at the Disrupt SF Startup Battlefield, aims to change the game with cannabinoids produced cleanly and cheaply in the lab — out of sugar.

Co-founder and CEO Sher Ali Butt says the idea struck him when he was working at cannabis testing lab Steep Hill. CBD, a compound found in the plant but in much lower concentrations than THC, the primary intoxicant, was producing extremely helpful pain and anxiety alleviation for some people without a high. The medicinal possibilities were obvious, but high-CBD strains of cannabis are not only uncommon, but a pain to cultivate and process for that purpose.

“CBD had all these applications, and I just thought that there’s got to be a better way to do this. The idea just stuck in my brain,” he told me.

After working on the problem on and off for years he decided to pursue it in earnest. Serendipitously, around this time he ran into Jacob Vogan, an old friend from college who was working in the field of bioengineering. It seemed like a natural fit to them to start the company together.

What CB Therapeutics has done is bioengineer microorganisms — specifically yeast — to manufacture cannabinoids out of plain-old sugars. This type of bioreactor isn’t a new idea; yeast and other organisms are used to create and isolate lots of drugs and substances.

“The vitamin C that we take in tablets, for instance — they didn’t squeeze oranges and lemons to get that,” Butt points out. “There isn’t enough agriculture to supply the global demand. It was produced synthetically and put in a box.”

CB Therapeutics is just doing the same thing for cannabinoids, and not just CBD.

“There are 118 cannabinoids, and only five have been studied,” Butt says. “These compounds are like .1, .01, even .001 percent in the cannabis bud. When you want to extract these, a kilogram can be like $100,000 to $350,000. How is someone supposed to do research with that?”

But the yeast don’t care. They take in sugar and output whatever molecule their biosynthesis pathway has been modified to produce — within reason, of course. You couldn’t output large, complex non-organics, but cannabinoids — even the rare ones — are well within their capabilities.

“The only thing we need to add is sugar — that’s the beauty of what we’ve done,” Butt beamed. “The yeast platform is agnostic, it makes everything for the same price.”

This has several benefits. First, it can bring down the price of a known and useful cannabinoid like CBD. Second, it allows the rarer ones to be studied for a reasonable price, and eventually distributed as well. And third, it takes pressure off the agricultural component of the cannabis industry.

That last is not only good from an ecological perspective, since demand is growing and these plants require a lot of water and land, but from the health side as well. Butt points out that a huge majority of cannabis products tested are found to be contaminated to some degree with pesticides and other unwanted compounds.

It’s getting better as the marijuana industry becomes an above-board one, but the problem is far from eliminated, and at any rate pesticides and other potentially harmful chemicals don’t cease to be a nuisance just because something is legal. The risk is there for the foreseeable future that, ironically, the “natural” option of using the plant itself is going to produce more impurities in the product, not less. But the yeast don’t — can’t, really — taint the product. So what comes out of the bioreactor should theoretically be as pure as the driven snow. (CB Therapeutics does test it, of course.)

It’s worth noting that the company’s main intellectual property is is the cannabinoid biosynthesis pathway it has developed. That hadn’t been fully documented or explored, Butt says, until their work.

Butt sees this change as more or less just the latest example of a useful class of molecules going from difficult to relatively easy to acquire.

“When you aren’t able to provide for the demand, that makes prices artificially high. People are going out and spending tens of thousands on CBD, for medical applications,” he said. “Insulin used to be harvested from pig pancreases, then Genentech solved that. Aspirin used to come from tree bark. This is inevitable for many compounds. We need to bring the cannabis price down to where anybody can use it.”

The pricing and volume are still somewhat of a question mark — once testing and the regulatory hurdles are taken care of, like any pharmaceutical it’s going to be a moving target. But scaling production shouldn’t be hard should the demand grow, and the backlog of new cannabinoids to isolate for testing should provide a source of income as well.

Medicine can be a risky sector for startups but CB Therapeutics seems to have it as close to sewn up as one can reasonably expect; in a way it’s almost alchemical, this ability to cheaply produce something so valuable. But really, it’s just science.

More TechCrunch

Google says the new SDK would help Google expand on its core mission of connecting the right audience to the right content at the right time.

Google launches a new Android feature to drive users back into their installed apps

Jolla has taken the official wraps off the first version of its personal server-based AI assistant in the making. The reborn startup is building a privacy-focused AI device — aka…

Jolla debuts privacy-focused AI hardware

OpenAI is removing one of the voices used by ChatGPT after users found that it sounded similar to Scarlett Johansson, the company announced on Monday. The voice, called Sky, is…

OpenAI to remove ChatGPT’s Scarlett Johansson-like voice

Consumer demand for the latest AI technology is heating up. The launch of OpenAI’s latest flagship model, GPT-4o, has now driven the company’s biggest-ever spike in revenue on mobile, despite…

ChatGPT’s mobile app revenue saw biggest spike yet following GPT-4o launch

Dating app maker Bumble has acquired Geneva, an online platform built around forming real-world groups and clubs. The company said that the deal is designed to help it expand its…

Bumble buys community building app Geneva to expand further into friendships

CyberArk — one of the army of larger security companies founded out of Israel — is acquiring Venafi, a specialist in machine identity, for $1.54 billion. 

CyberArk snaps up Venafi for $1.54B to ramp up in machine-to-machine security

Founder-market fit is one of the most crucial factors in a startup’s success, and operators (someone involved in the day-to-day operations of a startup) turned founders have an almost unfair advantage…

OpenseedVC, which backs operators in Africa and Europe starting their companies, reaches first close of $10M fund

A Singapore High Court has effectively approved Pine Labs’ request to shift its operations to India.

Pine Labs gets Singapore court approval to shift base to India

The AI Safety Institute, a U.K. body that aims to assess and address risks in AI platforms, has said it will open a second location in San Francisco. 

UK opens office in San Francisco to tackle AI risk

Companies are always looking for an edge, and searching for ways to encourage their employees to innovate. One way to do that is by running an internal hackathon around a…

Why companies are turning to internal hackathons

Featured Article

I’m rooting for Melinda French Gates to fix tech’s broken ‘brilliant jerk’ culture

Women in tech still face a shocking level of mistreatment at work. Melinda French Gates is one of the few working to change that.

24 hours ago
I’m rooting for Melinda French Gates to fix tech’s  broken ‘brilliant jerk’ culture

Blue Origin has successfully completed its NS-25 mission, resuming crewed flights for the first time in nearly two years. The mission brought six tourist crew members to the edge of…

Blue Origin successfully launches its first crewed mission since 2022

Creative Artists Agency (CAA), one of the top entertainment and sports talent agencies, is hoping to be at the forefront of AI protection services for celebrities in Hollywood. With many…

Hollywood agency CAA aims to help stars manage their own AI likenesses

Expedia says Rathi Murthy and Sreenivas Rachamadugu, respectively its CTO and senior vice president of core services product & engineering, are no longer employed at the travel booking company. In…

Expedia says two execs dismissed after ‘violation of company policy’

Welcome back to TechCrunch’s Week in Review. This week had two major events from OpenAI and Google. OpenAI’s spring update event saw the reveal of its new model, GPT-4o, which…

OpenAI and Google lay out their competing AI visions

When Jeffrey Wang posted to X asking if anyone wanted to go in on an order of fancy-but-affordable office nap pods, he didn’t expect the post to go viral.

With AI startups booming, nap pods and Silicon Valley hustle culture are back

OpenAI’s Superalignment team, responsible for developing ways to govern and steer “superintelligent” AI systems, was promised 20% of the company’s compute resources, according to a person from that team. But…

OpenAI created a team to control ‘superintelligent’ AI — then let it wither, source says

A new crop of early-stage startups — along with some recent VC investments — illustrates a niche emerging in the autonomous vehicle technology sector. Unlike the companies bringing robotaxis to…

VCs and the military are fueling self-driving startups that don’t need roads

When the founders of Sagetap, Sahil Khanna and Kevin Hughes, started working at early-stage enterprise software startups, they were surprised to find that the companies they worked at were trying…

Deal Dive: Sagetap looks to bring enterprise software sales into the 21st century

Keeping up with an industry as fast-moving as AI is a tall order. So until an AI can do it for you, here’s a handy roundup of recent stories in the world…

This Week in AI: OpenAI moves away from safety

After Apple loosened its App Store guidelines to permit game emulators, the retro game emulator Delta — an app 10 years in the making — hit the top of the…

Adobe comes after indie game emulator Delta for copying its logo

Meta is once again taking on its competitors by developing a feature that borrows concepts from others — in this case, BeReal and Snapchat. The company is developing a feature…

Meta’s latest experiment borrows from BeReal’s and Snapchat’s core ideas

Welcome to Startups Weekly! We’ve been drowning in AI news this week, with Google’s I/O setting the pace. And Elon Musk rages against the machine.

Startups Weekly: It’s the dawning of the age of AI — plus,  Musk is raging against the machine

IndieBio’s Bay Area incubator is about to debut its 15th cohort of biotech startups. We took special note of a few, which were making some major, bordering on ludicrous, claims…

IndieBio’s SF incubator lineup is making some wild biotech promises

YouTube TV has announced that its multiview feature for watching four streams at once is now available on Android phones and tablets. The Android launch comes two months after YouTube…

YouTube TV’s ‘multiview’ feature is now available on Android phones and tablets

Featured Article

Two Santa Cruz students uncover security bug that could let millions do their laundry for free

CSC ServiceWorks provides laundry machines to thousands of residential homes and universities, but the company ignored requests to fix a security bug.

3 days ago
Two Santa Cruz students uncover security bug that could let millions do their laundry for free

TechCrunch Disrupt 2024 is just around the corner, and the buzz is palpable. But what if we told you there’s a chance for you to not just attend, but also…

Harness the TechCrunch Effect: Host a Side Event at Disrupt 2024

Decks are all about telling a compelling story and Goodcarbon does a good job on that front. But there’s important information missing too.

Pitch Deck Teardown: Goodcarbon’s $5.5M seed deck

Slack is making it difficult for its customers if they want the company to stop using its data for model training.

Slack under attack over sneaky AI training policy

A Texas-based company that provides health insurance and benefit plans disclosed a data breach affecting almost 2.5 million people, some of whom had their Social Security number stolen. WebTPA said…

Healthcare company WebTPA discloses breach affecting 2.5 million people